CD146 is a potential marker for the diagnosis of malignancy in cervical and endometrial cancer

Zhang,Haofeng; Zhang,Jun; Wang,Zhaoqing; Lu,Di; Feng,Jing; Yang,Dongling; Chen,Xiuqin; Yan,Xiyun

doi:10.3892/ol.2013.1147

CD146 is a potential marker for the diagnosis of malignancy in cervical and endometrial cancer

Authors:
- Haofeng Zhang
- Jun Zhang
- Zhaoqing Wang
- Di Lu
- Jing Feng
- Dongling Yang
- Xiuqin Chen
- Xiyun Yan
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Capital Medical University Affiliated Beijing Anzhen Hospital, Institute of Beijing Heart, Lung and Blood Vessel Diseases, Chaoyang, Beijing 100029, P.R. China, Protein and Peptide Pharmaceutical Laboratory, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Chaoyang, Beijing 100101, P.R. China, Department of Obstetrics and Gynecology, The Fifth Affiliated Hospital of Zhengzhou University, Erqi, Zhengzhou 450000, P.R. China
Published online on: January 22, 2013 https://doi.org/10.3892/ol.2013.1147
Pages: 1189-1194

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cluster of differentiation 146 (CD146) is an endothelial cell adhesion molecule which is overexpressed in various types of malignant cancer, including ovarian cancer. However, whether CD146 is overexpressed in another two types of gynecological cancer, cervical cancer and endometrial cancer, remains unclear. In the present study, we showed that CD146 expression levels were higher in cells from cervical cancer and endometrial cancer compared with their corresponding normal tissues, using anti-CD146 mouse antibody AA4 (mAb AA4) and that mAb AA4 exhibited a high performance for specificity, sensitivity and positive predictive value in the detection of these two types of cancer. CD146 expression was positively and significantly correlated with the pathological subtype of cervical cancer and with the histological grade and depth of myometrial invasion in endometrial cancer. In addition, we confirmed that CD146 is present in the majority of blood vessels in cervical and endometrial cancer, suggesting that CD146 may be actively implicated in the metastasis of cervical and endometrial cancer via the vascular system. Thus, this study provides insights for further development of CD146 mAb in the detection of gynecological malignant cancer types and implies that a combined treatment strategy of anti-CD146 immunotherapy with other traditional chemo- or radiotherapy treatments may be a promising approach against cervical and endometrial cancer.

View Figures

View References

1	Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmüller G and Johnson JP: Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res. 47:841–845. 1987.
2	Lehmann JM, Riethmüller G and Johnson JP: MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA. 86:9891–9895. 1989. View Article : Google Scholar
3	Shih IM, Elder DE, Speicher D, Johnson JP and Herlyn M: Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res. 54:2514–2520. 1994.PubMed/NCBI
4	Shih IM, Elder DE, Hsu MY and Herlyn M: Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol. 145:837–845. 1994.PubMed/NCBI
5	Bardin N, Francès V, Lesaule G, Horschowski N, George F and Sampol J: Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun. 218:210–216. 1996. View Article : Google Scholar : PubMed/NCBI
6	Rummel MM, Sers C and Johnson JP: Phorbol ester and cyclic AMP-mediated regulation of the melanoma-associated cell adhesion molecule MUC18/MCAM. Cancer Res. 56:2218–2223. 1996.PubMed/NCBI
7	Xie S, Luca M, Huang S, et al: Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res. 57:2295–2303. 1997.PubMed/NCBI
8	Wu GJ, Wu MW, Wang C and Liu Y: Enforced expression of METCAM/MUC18 increases tumorigenesis of human prostate cancer LNCaP cells in nude mice. J Urol. 185:1504–1512. 2011. View Article : Google Scholar : PubMed/NCBI
9	Vainio O, Dunon D, Aïssi F, Dangy JP, McNagny KM and Imhof BA: HEMCAM, an adhesion molecule expressed by c-kit+ hemopoietic progenitors. J Cell Biol. 135:1655–1668. 1996.PubMed/NCBI
10	Taira E, Takaha N, Taniura H, Kim CH and Miki N: Molecular cloning and functional expression of gicerin, a novel cell adhesion molecule that binds to neurite outgrowth factor. Neuron. 12:861–872. 1994. View Article : Google Scholar : PubMed/NCBI
11	Aldovini D, Demichelis F, Doglioni C, et al: M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer. 119:1920–1926. 2006. View Article : Google Scholar : PubMed/NCBI
12	Feng G, Fang F, Liu C, Zhang F, Huang H and Pu C: CD146 gene expression in clear cell renal cell carcinoma: a potential marker for prediction of early recurrence after nephrectomy. Int Urol Nephrol. 44:1663–1669. 2012. View Article : Google Scholar : PubMed/NCBI
13	Liu WF, Ji SR, Sun JJ, et al: CD146 Expression Correlates with Epithelial-Mesenchymal Transition Markers and a Poor Prognosis in Gastric Cancer. Int J Mol Sci. 13:6399–6406. 2012. View Article : Google Scholar : PubMed/NCBI
14	Zeng Q, Li W, Lu D, et al: CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA. 109:1127–1132. 2012. View Article : Google Scholar : PubMed/NCBI
15	Ouhtit A, Gaur RL, Abd Elmageed ZY, et al: Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta. 1795:130–136. 2009.PubMed/NCBI
16	Bu P, Gao L, Zhuang J, Feng J, Yang D and Yan X: Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-kappaB activation. Mol Cancer Ther. 5:2872–2878. 2006. View Article : Google Scholar : PubMed/NCBI
17	Wellbrock J and Fiedler W: CD146: a new partner for VEGFR2. Blood. 120:2164–2165. 2012. View Article : Google Scholar : PubMed/NCBI
18	Johnson JP, Rothbächer U and Sers C: The progression associated antigen MUC18: a unique member of the immunoglobulin supergene family. Melanoma Res. 3:337–340. 1993. View Article : Google Scholar : PubMed/NCBI
19	Zhang Y, Zheng C, Zhang J, et al: Generation and characterization of a panel of monoclonal antibodies against distinct epitopes of human CD146. Hybridoma (Larchmt). 27:345–352. 2008. View Article : Google Scholar : PubMed/NCBI
20	Mathew A and George PS: Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix - worldwide. Asian Pac J Cancer Prev. 10:645–650. 2009.PubMed/NCBI
21	Prat J: Prognostic parameters of endometrial carcinoma. Hum Pathol. 35:649–662. 2004. View Article : Google Scholar
22	Kang Y, Wang F, Feng J, et al: Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. Cell Res. 16:313–318. 2006. View Article : Google Scholar : PubMed/NCBI
23	Zheng C, Qiu Y, Zeng Q, et al: Endothelial CD146 is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization. Int J Biochem Cell Biol. 41:2163–2172. 2009. View Article : Google Scholar : PubMed/NCBI
24	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
25	Nolen BM and Lokshin AE: Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol. 8:55–71. 2012. View Article : Google Scholar : PubMed/NCBI
26	Tanyi JL and Scholler N: Oncology biomarkers for gynecologic malignancies. Front Biosci (Elite Ed). 4:1097–1110. 2012. View Article : Google Scholar : PubMed/NCBI
27	Chmura A, Wojcieszek A, Mrochem J, et al: Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma. Ginekol Pol. 80:361–366. 2009.(In Polish).
28	Micke O, Bruns F, Schäfer U, Prott FJ and Willich N: The impact of squamous cell carcinoma (SCC) antigen in patients with advanced cancer of uterine cervix treated with (chemo-)radiotherapy. Anticancer Res. 25:1663–1666. 2005.PubMed/NCBI
29	Jankovic MM and Milutinovic BS: Glycoforms of CA125 antigen as a possible cancer marker. Cancer Biomark. 4:35–42. 2008.PubMed/NCBI